Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Atherosclerosis - Pipeline Review, H2 2013

Published: Aug-2013 | Format: PDF | Global Markets Direct | Number of pages: 251 | Code: MRS - 988

Global Markets Directs, 'Atherosclerosis Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Atherosclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atherosclerosis. Atherosclerosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope


A snapshot of the global therapeutic scenario for Atherosclerosis.
A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Atherosclerosis pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy


Identify and understand important and diverse types of therapeutics under development for Atherosclerosis.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atherosclerosis Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Atherosclerosis 12
Atherosclerosis Therapeutics under Development by Companies 14
Atherosclerosis Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Atherosclerosis Therapeutics - Products under Development by Companies 25
Atherosclerosis Therapeutics - Products under Investigation by Universities/Institutes 30
Companies Involved in Atherosclerosis Therapeutics Development 31
Bristol-Myers Squibb Company 31
Aastrom Biosciences, Inc. 32
Johnson & Johnson 33
AstraZeneca PLC 34
Eli Lilly and Company 35
GlaxoSmithKline plc 36
Isis Pharmaceuticals, Inc. 37
Daiichi Sankyo Company, Ltd 38
Merck & Co., Inc. 39
Novartis AG 40
Dong-A Pharmaceutical Co., Ltd. 41
Dr. Reddy's Laboratories Limited 42
Zydus Cadila Healthcare Limited 43
Bayer AG 44
Genfit 45
PROLOR Biotech, Inc. 46
CSL Limited 47
Yuhan Corporation 48
Anagen Therapeutics, Inc. 49
Cytos Biotechnology AG 50
Pronova BioPharma ASA 51
AFFiRiS AG 52
CIMAB S.A. 53
Jenrin Discovery, Inc. 54
Spherix Incorporated 55
Arisaph Pharmaceuticals, Inc. 56
Funxional Therapeutics Ltd 57
GenKyoTex S.A. 58
Vascular Biogenics Ltd. 59
Cardax Pharmaceuticals, Inc. 60
KineMed, Inc. 61
BRIDGE BIORESEARCH PLC 62
ChemoCentryx, Inc. 63
Provid Pharmaceuticals, Inc. 64
Vitae Pharmaceuticals, Inc. 65
Athera Biotechnologies AB 66
NasVax Ltd. 67
Regulus Therapeutics Inc. 68
Centocor Ortho Biotech, Inc. 69
Esperion Therapeutics, Inc. 70
Vascular Pharmaceuticals, Inc. 71
Inserm Transfert SA 72
SelectX Pharmaceuticals, Inc. 73
InVasc Therapeutics, Inc. 74
DoNatur GmbH 75
Artery Therapeutics, Inc. 76
Atherosclerosis - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 84
anacetrapib - Drug Profile 84
XL-652 - Drug Profile 86
darapladib - Drug Profile 88
vorapaxar sulfate - Drug Profile 90
canakinumab - Drug Profile 92
FX-141-L - Drug Profile 96
FX-87-L - Drug Profile 97
SOL-02 - Drug Profile 98
ixmyelocel-T - Drug Profile 99
DRL-17822 - Drug Profile 102
SPX-7233801 - Drug Profile 103
VB-201 - Drug Profile 104
REV D-4F - Drug Profile 106
Lipase Inhibitors - Drug Profile 107
Cardiovascular Program - Drug Profile 108
CSL-112 - Drug Profile 109
JD-2000 Series - Drug Profile 110
JD-5000 Series - Drug Profile 111
JD-6000 Series - Drug Profile 112
CYT018-IL1aQb - Drug Profile 113
MDCO-216 - Drug Profile 114
AT-5261 - Drug Profile 116
GKT-137831 - Drug Profile 117
CDX-085 - Drug Profile 118
(ezetimibe + atorvastatin calcium) - Drug Profile 120
aliskiren fumarate - Drug Profile 122
evacetrapib - Drug Profile 124
INV-404 - Drug Profile 126
INV-405 - Drug Profile 127
ATH-03 - Drug Profile 128
Drug For Atherosclerotic Plaque - Drug Profile 129
Annexin A-5 - Drug Profile 130
PC-mAb - Drug Profile 131
Anti-CD3 Mab - Drug Profile 133
Protein-Based HDL Therapies - Drug Profile 135
Anti microRNA-33a/b - Drug Profile 137
(SPX-106 + D-tagatose) - Drug Profile 138
CD14 Project - Drug Profile 140
PRC-4016 - Drug Profile 141
AHRO-001 - Drug Profile 142
Drug For Atherosclerosis - Drug Profile 144
ISIS-APOARx - Drug Profile 145
YH-Chem3 - Drug Profile 146
(aspirin + clopidogrel) - Drug Profile 147
ACP-501 - Drug Profile 148
Drug Targeting F11R - Drug Profile 150
Stem Cell Therapy - Drug Profile 152
COR-2 - Drug Profile 153
CideB Antisense Oligonucleotide - Drug Profile 154
MCS-18 - Drug Profile 155
Vaccine For Atherosclerosis - Drug Profile 157
KRP-206 - Drug Profile 158
CCX-771 - Drug Profile 159
Drug For Baroreflex Activity - Drug Profile 160
Progranulin - Drug Profile 161
ARA-290 - Drug Profile 162
VTP-4 - Drug Profile 164
microRNA-145-Based Gene Therapy - Drug Profile 165
VPI-2690-B - Drug Profile 166
Tanshinone IIA - Drug Profile 167
FX-5A - Drug Profile 168
Cell Migration Inhibitors - Drug Profile 169
ATI-829 - Drug Profile 170
S-Allymercapto-N-Acetylcysteine - Drug Profile 171
GKT-136901 - Drug Profile 172
melittin - Drug Profile 174
GQ-16 - Drug Profile 175
BAY-606583 - Drug Profile 176
3-hydroxyanthranilic acid - Drug Profile 177
NoX-1/4 Inhibitors - Drug Profile 178
Monoclonal Antibody Targeting Integrin Alpha V Beta 3 Receptor - Drug Profile 179
IL12B Inhibitors - Drug Profile 180
Hepcidin Inhibitors - Drug Profile 181
Bone Morphogenic Protein Inhibitors - Drug Profile 182
Atheroprotective Vaccine - Drug Profile 183
Chymase Inhibitors - Drug Profile 184
DS-1442 - Drug Profile 185
Anti-CD20 Monoclonal Antibody - Drug Profile 186
Stromal Interaction Molecule 1 Inhibitor - Drug Profile 187
JD-5006 - Drug Profile 188
JD-5037 - Drug Profile 189
DYB-186 - Drug Profile 190
Atherosclerosis Program - Drug Profile 191
Drug For Chronic Inflammatory Diseases - Drug Profile 192
CVX-210H - Drug Profile 193
Adenoviral Vector Based Human ABCG1 Gene Therapy - Drug Profile 194
AZ-876 - Drug Profile 195
Calcineurin Inhibitors - Drug Profile 196
LPDL Project - Drug Profile 197
Cannabinoid Receptor 2 Agonist - Drug Profile 198
Macrophage Migration Inhibitory Factor Program - Drug Profile 199
Lipoxygenase Inhibitors - Drug Profile 200
SYN-20110119RU - Drug Profile 201
Anti-CD97 Antibodies - Drug Profile 202
Stapled Apolipoproteins - Drug Profile 203
Anti Idiotype chP3R99Q Vaccine - Drug Profile 204
Atherosclerosis Therapeutics - Drug Profile Updates 205
Atherosclerosis Therapeutics - Discontinued Products 229
Atherosclerosis Therapeutics - Dormant Products 231
Atherosclerosis - Product Development Milestones 236
Featured News & Press Releases 236

Appendix 244
Methodology 244
Coverage 244
Secondary Research 244
Primary Research 244
Expert Panel Validation 244
Contact Us 245
Disclaimer 245


List of Tables

Number of Products Under Development for Atherosclerosis, H2 2013 18
Products under Development for Atherosclerosis - Comparative Analysis, H2 2013 19
Number of Products under Development by Companies, H2 2013 21
Number of Products under Development by Companies, H2 2013 (Contd..1) 22
Number of Products under Development by Companies, H2 2013 (Contd..2) 23
Number of Products under Development by Companies, H2 2013 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2013 26
Comparative Analysis by Late Stage Development, H2 2013 27
Comparative Analysis by Mid Clinical Stage Development, H2 2013 28
Comparative Analysis by Early Clinical Stage Development, H2 2013 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 30
Products under Development by Companies, H2 2013 31
Products under Development by Companies, H2 2013 (Contd..1) 32
Products under Development by Companies, H2 2013 (Contd..2) 33
Products under Development by Companies, H2 2013 (Contd..3) 34
Products under Development by Companies, H2 2013 (Contd..4) 35
Products under Investigation by Universities/Institutes, H2 2013 36
Bristol-Myers Squibb Company, H2 2013 37
Aastrom Biosciences, Inc., H2 2013 38
Johnson & Johnson, H2 2013 39
AstraZeneca PLC, H2 2013 40
Eli Lilly and Company, H2 2013 41
GlaxoSmithKline plc, H2 2013 42
Isis Pharmaceuticals, Inc., H2 2013 43
Daiichi Sankyo Company, Ltd, H2 2013 44
Merck & Co., Inc., H2 2013 45
Novartis AG, H2 2013 46
Dong-A Pharmaceutical Co., Ltd., H2 2013 47
Dr. Reddy's Laboratories Limited, H2 2013 48
Zydus Cadila Healthcare Limited, H2 2013 49
Bayer AG, H2 2013 50
Genfit, H2 2013 51
PROLOR Biotech, Inc., H2 2013 52
CSL Limited, H2 2013 53
Yuhan Corporation, H2 2013 54
Anagen Therapeutics, Inc., H2 2013 55
Cytos Biotechnology AG, H2 2013 56
Pronova BioPharma ASA, H2 2013 57
AFFiRiS AG, H2 2013 58
CIMAB S.A., H2 2013 59
Jenrin Discovery, Inc., H2 2013 60
Spherix Incorporated, H2 2013 61
Arisaph Pharmaceuticals, Inc., H2 2013 62
Funxional Therapeutics Ltd, H2 2013 63
GenKyoTex S.A., H2 2013 64
Vascular Biogenics Ltd., H2 2013 65
Cardax Pharmaceuticals, Inc., H2 2013 66
KineMed, Inc., H2 2013 67
BRIDGE BIORESEARCH PLC, H2 2013 68
ChemoCentryx, Inc., H2 2013 69
Provid Pharmaceuticals, Inc., H2 2013 70
Vitae Pharmaceuticals, Inc., H2 2013 71
Athera Biotechnologies AB, H2 2013 72
NasVax Ltd., H2 2013 73
Regulus Therapeutics Inc., H2 2013 74
Centocor Ortho Biotech, Inc., H2 2013 75
Esperion Therapeutics, Inc., H2 2013 76
Vascular Pharmaceuticals, Inc., H2 2013 77
Inserm Transfert SA, H2 2013 78
SelectX Pharmaceuticals, Inc., H2 2013 79
InVasc Therapeutics, Inc., H2 2013 80
DoNatur GmbH, H2 2013 81
Artery Therapeutics, Inc., H2 2013 82
Assessment by Monotherapy Products, H2 2013 83
Assessment by Combination Products, H2 2013 84
Assessment by Stage and Route of Administration, H2 2013 86
Assessment by Stage and Molecule Type, H2 2013 89
Atherosclerosis Therapeutics - Drug Profile Updates 211
Atherosclerosis Therapeutics - Discontinued Products 235
Atherosclerosis Therapeutics - Discontinued Products (Contd..1) 236
Atherosclerosis Therapeutics - Dormant Products 237
Atherosclerosis Therapeutics - Dormant Products (Contd..1) 238
Atherosclerosis Therapeutics - Dormant Products (Contd..2) 239
Atherosclerosis Therapeutics - Dormant Products (Contd..3) 240
Atherosclerosis Therapeutics - Dormant Products (Contd..4) 241 
List of Figures

Number of Products under Development for Atherosclerosis, H2 2013 18
Products under Development for Atherosclerosis - Comparative Analysis, H2 2013 19
Products under Development by Companies, H2 2013 20
Products under Investigation by Universities/Institutes, H2 2013 25
Late Stage Products, H2 2013 27
Mid Clinical Stage Products, H2 2013 28
Early Clinical Stage Products, H2 2013 29
Discovery and Pre-Clinical Stage Products, H2 2013 30
Assessment by Monotherapy Products, H2 2013 83
Assessment by Combination Products, H2 2013 84
Assessment by Route of Administration, H2 2013 85
Assessment by Stage and Route of Administration, H2 2013 86
Assessment by Molecule Type, H2 2013 87
Assessment by Stage and Molecule Type, H2 2013 88

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing